Here are the 10-Q quarterly reports from Kardigan, Inc. (KARD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KARD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KARD filings page.
Kardigan, Inc., a clinical-stage cardiovascular therapeutics company, reported larger losses as it scaled up after its June 22, 2026 IPO. For the six months ended June 30, 2026, the company recorded a net loss of $172.3 million, compared with $75.5 million a year earlier, driven mainly by higher research and development expense of $101.4 million and a $43.5 million non-cash increase in the fair value of contingent milestone liabilities.
The IPO raised $422.4 million in net proceeds and converted all preferred stock into common stock, lifting total cash, cash equivalents and investments to $660.7 million and total assets to $721.8 million as of June 30, 2026. Management states this liquidity is expected to fund operations for at least twelve months from the financial statement issuance date, alleviating prior substantial doubt about going concern. Kardigan remains pre-revenue, investing heavily in its pipeline, its Prolaio data platform, and acquisitions to support precision cardiovascular drug development.